Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access everolimus for metastatic renal cell carcinoma after VEGFR tyrosine kinase inhibitor failure or intolerance
NL-OMON33782Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus in renal cell carcinoma (RCC), sponsored by Novartis. Primary endpoints: Grade 3/4 adverse events and Serious adverse events. Started Mar 2009; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON33782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33782.